ICON plc - Ordinary Shares (ICLR): Price and Financial Metrics
GET POWR RATINGS... FREE!
ICLR POWR Grades
- Growth is the dimension where ICLR ranks best; there it ranks ahead of 92.99% of US stocks.
- The strongest trend for ICLR is in Momentum, which has been heading down over the past 31 weeks.
- ICLR's current lowest rank is in the Sentiment metric (where it is better than 24.7% of US stocks).
ICLR Stock Summary
- Icon Plc's market capitalization of $12,155,514,175 is ahead of 83.25% of US-listed equities.
- Revenue growth over the past 12 months for Icon Plc comes in at 67.86%, a number that bests 91.55% of the US stocks we're tracking.
- The volatility of Icon Plc's share price is greater than that of merely 11.32% US stocks with at least 200 days of trading history.
- If you're looking for stocks that are quantitatively similar to Icon Plc, a group of peers worth examining would be MORN, CIEN, PNR, AMED, and MKSI.
- Visit ICLR's SEC page to see the company's official filings. To visit the company's web site, go to www.iconplc.com.
ICLR Valuation Summary
- In comparison to the median Healthcare stock, ICLR's price/sales ratio is 13.89% higher, now standing at 4.1.
- Over the past 216 months, ICLR's price/sales ratio has gone up 2.
- Over the past 216 months, ICLR's price/sales ratio has gone up 2.
Below are key valuation metrics over time for ICLR.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| ICLR | 2019-01-02 | 3.9 | 5.8 | 24.5 | 20.5 |
| ICLR | 2015-09-03 | 3.0 | 4.8 | 26.4 | 21.8 |
| ICLR | 2015-09-01 | 3.0 | 4.7 | 26.2 | 21.6 |
| ICLR | 2009-01-23 | 1.8 | 2.9 | 20.2 | 15.7 |
| ICLR | 2004-12-21 | 1.8 | 2.4 | 20.5 | 13.5 |
| ICLR | 2004-04-20 | 2.2 | 3.7 | 27.6 | 19.3 |
ICLR Growth Metrics
- Its 4 year net cashflow from operations growth rate is now at 119.15%.
- Its 5 year price growth rate is now at 170.05%.
- Its 2 year price growth rate is now at 37.06%.
The table below shows ICLR's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2020-12-31 | 2,797.288 | 568.035 | 332.331 |
| 2019-12-31 | 2,805.839 | 412.541 | 373.986 |
| 2018-12-31 | 2,595.777 | 268.639 | 322.656 |
| 2017-12-31 | 1,758.439 | 383.082 | 281.488 |
| 2016-12-31 | 1,666.487 | 259.204 | 262.179 |
| 2015-12-31 | 1,574.978 | 279.531 | 239.539 |
ICLR Price Target
For more insight on analysts targets of ICLR, see our ICLR price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $205.14 | Average Broker Recommendation | 1.72 (Moderate Buy) |
ICLR Stock Price Chart Interactive Chart >
ICLR Price/Volume Stats
| Current price | $244.08 | 52-week high | $250.24 |
| Prev. close | $246.55 | 52-week low | $168.76 |
| Day low | $242.29 | Volume | 1,925,300 |
| Day high | $250.24 | Avg. volume | 753,063 |
| 50-day MA | $218.89 | Dividend yield | N/A |
| 200-day MA | $204.75 | Market Cap | 12.90B |
ICON plc - Ordinary Shares (ICLR) Company Bio
ICON Public Limited Company provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. The company was founded in 1990 and is based in Dublin, Ireland.
ICLR Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $244.08 | $140.92 | -39% |
We started the process of determining a valid price forecast for Icon Plc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Icon Plc ranked in the 41th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. As for the metrics that stood out in our discounted cash flow analysis of Icon Plc, consider:
- The company's debt burden, as measured by earnings divided by interest payments, is 30.2 -- which is good for besting 83.55% of its peer stocks (US stocks in the Healthcare sector with positive cash flow).
- The business' balance sheet reveals debt to be 3% of the company's capital (with equity being the remaining amount). Approximately just 13.53% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
- ICLR's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 3%; for context, that number is higher than 51.09% of tickers in our DCF set.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -40% |
| 1% | -40% |
| 2% | -39% |
| 3% | -38% |
| 4% | -38% |
| 5% | -37% |
Want more companies with a valuation profile/forecast similar to that of Icon Plc? See ICUI, VIVO, UTHR, ABT, and FZMD.
Latest ICLR News From Around the Web
Below are the latest news stories about Icon Plc that investors may wish to consider to help them evaluate ICLR as an investment opportunity.
Icon PLC (ICLR) Soars to 52-Week High, Time to Cash Out?Icon PLC (ICLR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues. |
Surging Earnings Estimates Signal Upside for Icon PLC (ICLR) StockIcon PLC (ICLR) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions. |
Top Ranked Growth Stocks to Buy for July 26thICLR, DG, AN, and DVN made it to the Zacks Rank #1 (Strong Buy) growth stocks list on July 26, 2021 |
New Strong Buy Stocks for July 26thCRK, MATX, RGP, ESTE, and ICLR have been added to the Zacks Rank #1 (Strong Buy) List on July 26, 2021. |
Pharmacovigilance Market 2021 SWOT Analysis, Competitive Landscape and Significant Growth | Top Brands:Eli Lilly and Company, ICON plc, Elsevier, Chiltern, Atlantic Research Group, Mapi Group, AcceThis report studies the Pharmacovigilance Market with many aspects of the industry such as market size, market status, market trends and forecast. The report also provides brief information on competitors and opportunities for specific growth with the key market drivers. Find the comprehensive analysis of the Pharmacovigilance market segmented by company, region, type and applications [] |
ICLR Price Returns
| 1-mo | 13.48% |
| 3-mo | 9.96% |
| 6-mo | 22.33% |
| 1-year | 29.50% |
| 3-year | 69.57% |
| 5-year | 218.56% |
| YTD | 25.18% |
| 2020 | 13.21% |
| 2019 | 33.29% |
| 2018 | 15.21% |
| 2017 | 49.14% |
| 2016 | -3.22% |
Loading social stream, please wait...